The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation–positive metastatic melanoma patients (pts).
G. A. McArthur
Consultant or Advisory Role - Roche (U)
A. Ribas
Consultant or Advisory Role - Genentech; Roche
Honoraria - Genentech; Roche
P. B. Chapman
Consultant or Advisory Role - Roche
Research Funding - Roche
K. T. Flaherty
Consultant or Advisory Role - Genentech
K. B. Kim
Consultant or Advisory Role - Genentech; Roche
Honoraria - Genentech; Roche
Research Funding - Genentech; Roche
I. Puzanov
Consultant or Advisory Role - Roche
K. L. Nathanson
Research Funding - Plexxikon
R. J. Lee
Employment or Leadership Position - Roche
A. Koehler
Employment or Leadership Position - Roche
O. Spleiss
Employment or Leadership Position - Roche
G. Bollag
No relevant relationships to disclose
W. Wu
Employment or Leadership Position - Roche
K. Trunzer
Employment or Leadership Position - Roche
Stock Ownership - Roche
J. A. Sosman
Consultant or Advisory Role - Genentech; Roche
Honoraria - Genentech; Roche